Researching: Eli Lilly

Pulling real-time news, deal activity, and upcoming catalysts

Analyzing sources for "Eli Lilly"...

📚 RxInsider Coverage (10)

How cost and perception could reshape the GLP-1 market

Eli Lilly's weekly insulin jab Onswik set for NHS use if approved

How cost and perception could reshape the GLP-1 market

The Oral GLP-1 Tracker: Lilly's Foundayo builds scripts after disappointing Q2

Lilly's Zepbound remains physicians' favorite, even as oral obesity launches alter landscape

Lilly and Novo Nordisk score an early antitrust win, but the policy fight isn’t over

Eli Lilly raises 2026 outlook again as Q2 soars past estimates

Eli Lilly tops new biopharma ranking on launch success, development speed

Lilly's leap into psychedelics; peptides in the spotlight

Novo Nordisk’s GLP‑1 suit and Anthropic’s biotech push headline the week